{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06450366",
            "orgStudyIdInfo": {
                "id": "0616-018"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-0616-018",
                    "type": "OTHER",
                    "domain": "Merck"
                },
                {
                    "id": "2023-504920-25",
                    "type": "REGISTRY",
                    "domain": "EU CT"
                },
                {
                    "id": "U1111-1290-3888",
                    "type": "OTHER",
                    "domain": "UTN"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn",
            "officialTitle": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-evaluate-the-efficacy-and-safety-of-enlicitide-decanoate-mk-oral-inhibitor-compared-with-ezetimibe-or-bempedoic-acid-or-ezetimibe-and-bempedoic-acid-in-adults-with-hypercholesterolemia-mk-coralreef-addon"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-21",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-22",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-04",
            "studyFirstSubmitQcDate": "2024-06-04",
            "studyFirstPostDateStruct": {
                "date": "2024-06-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to assess whether enlicitide decanoate is superior to ezetimibe or bempedoic acid or ezetimibe + bempedoic acid in reducing LDL-C in participants with hypercholesterolemia, and to evaluate its safety and tolerability. The primary study hypotheses are enlicitide decanoate is superior to ezetimibe, bempedoic acid, and ezetimibe + bempedoic acid on mean percent change from baseline in LDL-C at week 8."
        },
        "conditionsModule": {
            "conditions": [
                "Hypercholesterolemia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 300,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Enlicitide Decanoate",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive enlicitide decanoate 20mg, ezetimibe-matching placebo, and bempedoic acid-matching placebo once daily (QD) orally up to approximately 56 days.",
                    "interventionNames": [
                        "Drug: Enlicitide Decanoate",
                        "Other: Placebo for Ezetimibe",
                        "Other: Placebo for Bempedoic Acid"
                    ]
                },
                {
                    "label": "Ezetimibe",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants receive ezetimibe 10mg, enlicitide decanoate-matching placebo, and bempedoic acid-matching placebo QD orally up to approximately 56 days.",
                    "interventionNames": [
                        "Drug: Ezetimibe",
                        "Other: Placebo for Enlicitide Decanoate",
                        "Other: Placebo for Bempedoic Acid"
                    ]
                },
                {
                    "label": "Bempedoic Acid",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants receive bempedoic acid 180mg, ezetimibe-matching placebo, and enlicitide decanoate-matching placebo QD orally up to approximately 56 days.",
                    "interventionNames": [
                        "Drug: Bempedoic Acid",
                        "Other: Placebo for Enlicitide Decanoate",
                        "Other: Placebo for Ezetimibe"
                    ]
                },
                {
                    "label": "Ezetimibe + Bempedoic Acid",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants receive ezetimibe 10 mg, bempedoic acid 180mg, enlicitide decanoate-matching placebo orally QD for approximately 56 days.",
                    "interventionNames": [
                        "Drug: Ezetimibe",
                        "Drug: Bempedoic Acid",
                        "Other: Placebo for Enlicitide Decanoate"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Enlicitide Decanoate",
                    "description": "Administered orally.",
                    "armGroupLabels": [
                        "Enlicitide Decanoate"
                    ],
                    "otherNames": [
                        "MK-0616"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ezetimibe",
                    "description": "Administered orally.",
                    "armGroupLabels": [
                        "Ezetimibe",
                        "Ezetimibe + Bempedoic Acid"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bempedoic Acid",
                    "description": "Administered orally.",
                    "armGroupLabels": [
                        "Bempedoic Acid",
                        "Ezetimibe + Bempedoic Acid"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo for Enlicitide Decanoate",
                    "description": "Administered orally.",
                    "armGroupLabels": [
                        "Bempedoic Acid",
                        "Ezetimibe",
                        "Ezetimibe + Bempedoic Acid"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo for Ezetimibe",
                    "description": "Administered orally.",
                    "armGroupLabels": [
                        "Bempedoic Acid",
                        "Enlicitide Decanoate"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo for Bempedoic Acid",
                    "description": "Administered orally.",
                    "armGroupLabels": [
                        "Enlicitide Decanoate",
                        "Ezetimibe"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean Percent Change from Baseline in LDL-C at Day 56",
                    "description": "Blood samples will be collected at baseline and after 56 days of treatment to assess mean percentage change in LDL-C. The percent change from baseline in LDL-C at Day-56 will be reported.",
                    "timeFrame": "Baseline and Day 56"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mean Percent Change from Baseline in Apolipoprotein B (ApoB) at Day 56",
                    "description": "Blood samples will be collected at baseline and on day 56 of treatment to assess mean percent change in ApoB. The percent change from baseline in ApoB at Day 56 will be reported.",
                    "timeFrame": "Baseline and Day 56"
                },
                {
                    "measure": "Mean Percent Change from Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56",
                    "description": "Blood samples will be collected at baseline and on day 56 of treatment to assess mean percent change in non-HDL-C. The percent change from baseline in non-HDL-C at 56 days will be reported.",
                    "timeFrame": "Baseline and Day 56"
                },
                {
                    "measure": "Percent Change from Baseline in Lipoprotein(a) Levels (Lp[a])",
                    "description": "Blood samples will be collected at baseline and on day 56 of treatment to assess percent change in Lp(a) levels. The change from baseline at Day 56 will be reported.",
                    "timeFrame": "Baseline and Day 56"
                },
                {
                    "measure": "Percentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and \u226550% Reduction from Baseline",
                    "description": "The percentage of participants who have an LDL-C \\<70 mg/dL and \\>50% reduction from baseline at day 56 will be reported.",
                    "timeFrame": "Baseline and Day 56"
                },
                {
                    "measure": "Percentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and \u226550% Reduction from Baseline",
                    "description": "The percentage of participants who have an LDL-C \\<55 mg/dL and \\>50% reduction from baseline at day 56 will be reported.",
                    "timeFrame": "Baseline and Day 56"
                },
                {
                    "measure": "Number of Participants With \u22651 Adverse Event (AE)",
                    "description": "An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.",
                    "timeFrame": "Up to Approximately 112 days"
                },
                {
                    "measure": "Number of Participants Discontinuing from Study Therapy Due to AE",
                    "description": "An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.",
                    "timeFrame": "Up to Approximately 56 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has either a) history of a major atherosclerotic cardiovascular disease (ASCVD) event or b) if no history of a major ASCVD event, has intermediate to high risk for development of a first major ASCVD event\n* Has fasted lipid values (evaluated by the central laboratory) at Visit 1 (Screening) as follows: a) history of a major ASCVD event with LDL-C \u226555 mg/dL (\u22651.42 mmol/L) OR b) No history of a major ASCVD event with LDL-C \u226570 mg/dL (\u22651.81 mmol/L)\n* Is treated with a low, moderate, or high intensity statin (\u00b1non-statin lipid lowering therapy \\[LLT\\])\n* Is on a stable dose of all background LLTs with no planned medication or dose changes during the study\n* Is an individual of any sex/gender, from 18 years of age inclusive, at the time of providing the informed consent\n\nExclusion Criteria:\n\n* Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous familial hypercholesterolemia (HeFH), or double HeFH\n* Has New York Heart Association class IV heart failure, or last known left ventricular ejection fraction \u226425% by any imaging method, or had a heart failure hospitalization within 3 months before Visit 1 (Screening)\n* Participants with a history of tendon disorder or tendon rupture\n* Participants with a history of gout\n* Is undergoing or previously underwent an LDL-C apheresis program within 3 months before Visit 1 (Screening) or plans to initiate an LDL-C apheresis program\n* Was previously treated/is being treated with certain other cholesterol lowering medications, including ezetimibe, bempedoic acid, or protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate washout",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Trials Research ( Site 1509)",
                    "status": "RECRUITING",
                    "city": "Lincoln",
                    "state": "California",
                    "zip": "95648",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "916-434-8230"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.89156,
                        "lon": -121.29301
                    }
                },
                {
                    "facility": "Healthcare Research Network - Chicago ( Site 1507)",
                    "status": "RECRUITING",
                    "city": "Flossmoor",
                    "state": "Illinois",
                    "zip": "60422",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "708-388-2245"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.54281,
                        "lon": -87.68477
                    }
                },
                {
                    "facility": "L-MARC Research Center ( Site 1501)",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "502-515-5672"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Velocity Clinical Research Rockville ( Site 1503)",
                    "status": "RECRUITING",
                    "city": "Rockville",
                    "state": "Maryland",
                    "zip": "20854",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "301-762-5020"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.084,
                        "lon": -77.15276
                    }
                },
                {
                    "facility": "Velocity Clinical Research, Gulfport ( Site 1505)",
                    "status": "RECRUITING",
                    "city": "Gulfport",
                    "state": "Mississippi",
                    "zip": "39503",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "228-388-4862"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.36742,
                        "lon": -89.09282
                    }
                },
                {
                    "facility": "Piedmont Research Partners ( Site 1506)",
                    "status": "RECRUITING",
                    "city": "Fort Mill",
                    "state": "South Carolina",
                    "zip": "29707",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "803-802-4561"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.00737,
                        "lon": -80.94508
                    }
                },
                {
                    "facility": "Rainier Clinical Research Center ( Site 1502)",
                    "status": "RECRUITING",
                    "city": "Renton",
                    "state": "Washington",
                    "zip": "98057",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "425-251-1720"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.48288,
                        "lon": -122.21707
                    }
                },
                {
                    "facility": "The Medical Arts Health Research Group ( Site 1606)",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V7M 2H4",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "(888) 736-0667"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "North York Diagnostic and Cardiac Centre ( Site 1605)",
                    "status": "RECRUITING",
                    "city": "North York",
                    "state": "Ontario",
                    "zip": "M6B 3H7",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "4167830000"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.76681,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Diex Recherche Trois-Rivieres ( Site 1602)",
                    "status": "RECRUITING",
                    "city": "Trois-Rivieres",
                    "state": "Quebec",
                    "zip": "G9A 4P3",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "819-801-9797"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.34515,
                        "lon": -72.5477
                    }
                },
                {
                    "facility": "National Cheng Kung University Hospital-Internal Medicine ( Site 0403)",
                    "status": "RECRUITING",
                    "city": "Tainan",
                    "zip": "704",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "886623535354602"
                        }
                    ],
                    "geoPoint": {
                        "lat": 22.99083,
                        "lon": 120.21333
                    }
                },
                {
                    "facility": "Taipei Veterans General Hospital-Department of Medicine ( Site 0402)",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "11217",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "886228757516"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "http://www.merckclinicaltrials.com"
                },
                {
                    "label": "Plain Language Summary",
                    "url": "https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=0616-018&kw=0616-018"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006937",
                    "term": "Hypercholesterolemia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006949",
                    "term": "Hyperlipidemias"
                },
                {
                    "id": "D000050171",
                    "term": "Dyslipidemias"
                },
                {
                    "id": "D000052439",
                    "term": "Lipid Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9988",
                    "name": "Hypercholesterolemia",
                    "asFound": "Hypercholesterolemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10000",
                    "name": "Hyperlipidemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M10002",
                    "name": "Hyperlipoproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M26181",
                    "name": "Dyslipidemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27029",
                    "name": "Lipid Metabolism Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000581236",
                    "term": "8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid"
                },
                {
                    "id": "D000069438",
                    "term": "Ezetimibe"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000924",
                    "term": "Anticholesteremic Agents"
                },
                {
                    "id": "D000000960",
                    "term": "Hypolipidemic Agents"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000057847",
                    "term": "Lipid Regulating Agents"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2849",
                    "name": "PCSK9 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M409",
                    "name": "Ezetimibe",
                    "asFound": "Withdrawal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M340511",
                    "name": "8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid",
                    "asFound": "Progressive Multiple Sclerosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4243",
                    "name": "Anticholesteremic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4278",
                    "name": "Hypolipidemic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M28883",
                    "name": "Lipid Regulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Lipd",
                    "name": "Lipid Regulating Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                }
            ]
        }
    },
    "hasResults": false
}